Trastuzumab (Herceptin)

DRUG10 trials

Sponsors

Armando Santoro, MD, Nagoya City University, Alliance for Clinical Trials in Oncology, Institut Curie, Peking University Cancer Hospital & Institute

Conditions

Advanced/Metastatic Breast CancerAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Breast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)Breast Cancer, MetastaticBreast Neoplasm, ExerciseEarly Stage HER2+ Breast Cancer

Phase 2

Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients

TerminatedNCT00758134

Armando Santoro, MDNON-SMALL CELL LUNG CANCER

Start: 2008-07-31End: 2010-12-31Updated: 2013-05-29

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

RecruitingNCT07193394

Institut CurieMetastatic Breast Cancer ( HER2 Negative), Unresectable Breast Cancer

Start: 2026-01-31End: 2029-06-08Target: 20Updated: 2026-02-23

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Not yet recruitingNCT07527806

Peking University Cancer Hospital & InstituteBreast Cancer

Start: 2026-05-01End: 2029-12-31Target: 156Updated: 2026-04-17

Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)

Not yet recruitingNCT07565324

National Taiwan University HospitalHER-2 Positive Breast Cancer

Start: 2026-04-30End: 2032-12-31Target: 54Updated: 2026-05-04

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

RecruitingNCT07610720

Sun Yat-sen UniversityAdvanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer

Start: 2026-06-01End: 2029-11-01Target: 57Updated: 2026-05-28

Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer

Not yet recruitingNCT07772245

Polly A. Niravath, MDHER2-addicted Breast Cancer

Start: 2026-12-31End: 2032-12-31Target: 30Updated: 2026-08-19

Phase 3

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

RecruitingNCT06876714

Alliance for Clinical Trials in OncologyAnatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer

Start: 2025-09-17End: 2037-03-13Target: 1524Updated: 2026-09-02

Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC

RecruitingNCT07797218

Shanghai Jiao Tong University School of MedicineBreast Cancer Early Stage Breast Cancer (Stage 1-3)

Start: 2026-07-01End: 2030-06-30Target: 220Updated: 2026-09-01

Unknown Phase

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment

Active, not recruitingNCT06663787

Nagoya City UniversityBreast Cancer, Metastatic, HER2 + Breast Cancer

Start: 2024-04-01End: 2026-12-31Target: 50Updated: 2026-05-13

Oncology Treatment Related Ocular Surface Changes

CompletedNCT07666724

Semmelweis UniversityBreast Neoplasm, Exercise

Start: 2021-05-18End: 2026-05-31Updated: 2026-06-24